United Therapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of United Therapeutics with an Outperform rating and $330 price target. The firm says it has conducted an extensive review of the company’s broad commercial portfolio that is primarily focused on treating different types of pulmonary hypertension, in addition to the probability of success and market opportunities of its PH expansion efforts and pipeline platforms. Backed by multiple MEDACorp KOL calls, Leerink believes United Therapeutics has a leading role in the PH space, which, paired with thoughtful strategic development, allows them to meaningfully grow its current Tyvaso franchise by driving Tyvaso DPI uptake and pursuing expansion efforts into pulmonary hypertension associated with interstitial lung disease, where it has first-mover advantage.